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Abstract The EANM 2015 Annual Congress, held from
October 10th to 14th in Hamburg, Germany, was outstanding
in many respects. With 5550 participants, this was by far the
largest European congress concerning nuclear medicine.More
than 1750 scientific presentations were submitted, with more
than 250 abstracts from young scientists, indicating that the
future success of our discipline is fuelled by a high number of
young individuals becoming involved in a multitude of scien-
tific activities. Significant improvements have been made in
molecular imaging of cancer, particularly in prostate cancer.
PSMA-directed PET/CT appears to become a new gold stan-
dard for staging and restaging purposes. Novel tumour specif-
ic compounds have shown their potential for target identifica-
tion also in other solid neoplasms and further our understand-
ing of tumour biology and heterogeneity. In addition, a variety
of nuclear imaging techniques guiding surgical interventions
have been introduced. A particular focus of the congress was
put on targeted, radionuclide based therapies. Novel
theranostic concepts addressing also tumour entities with high
incidence rates such as prostate cancer, melanoma, and lym-
phoma, have shown effective anti-tumour activity. Strategies
have been presented to improve further already established
therapeutic regimens such as somatostatin receptor based ra-
dio receptor therapy for treating advanced neuroendocrine tu-
mours. Significant contributions were presented also in the
neurosciences track. An increasing number of target structures
of high interest in neurology and psychiatry are now available
for PET and SPECT imaging, facilitating specific imaging of
different subtypes of dementia and movement disorders as
well as neuroinflammation. Major contributions in the cardio-
vascular track focused on further optimization of cardiac per-
fusion imaging by reducing radiation exposure, reducing
scanning time, and improving motion correction. Besides cor-
onary artery disease, many contributions focused on cardiac
inflammation, cardiac sarcoidosis, and specific imaging of
large vessel vasculitis. The physics and instrumentation track
included many highlights such as novel, high resolution scan-
ners. The most noteworthy news and developments of this
meeting were summarized in the highlights lecture. Only 55
scientific contributions were mentioned, and hence they rep-
resent only a brief summary, which is outlined in this article.
For a more detailed view, all presentations can be accessed by
the online version of the European Journal of Nuclear
Medicine andMolecular Imaging (Volume 42, Supplement 1).
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Introduction
From October 10–14, 2015, 5550 participants met at the 28th
Annual Meeting of the European Association of Nuclear
Medicine (EANM) in Hamburg, Germany. This is by far the
largest European congress related to nuclear medicine and was
chaired by Prof. Wim Oyen, representing EANM’s scientific
committee, organizing a highly multidisciplinary programme
comprising 425 oral and 1208 poster presentations. Besides
regular participants, 775 professionals followed the congress
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programme online via the EANM live stream.More than 1000
attendees were coming from non-European countries, with
strongest representations from USA, Japan, Australia, and
Canada.
Twenty sessions on continuing education (medical doctors
and technologists), four plenary sessions, 24 symposia and
pre-symposia surrounded the scientific programme. In total,
1767 abstracts for the scientific programme were received,
1530 abstracts were accepted (rejection rate, 13.4 %), the third
highest number in the history of the meeting, only topped by
last year and the 25th EANM anniversary meeting in Milan
2012 (Fig. 1). In addition, 137 technologist’s abstracts were
included in the programme.
In total, abstracts were submitted from 83 different coun-
tries worldwide (Fig. 2). The highest number of abstracts was
received, as in the years before, from Italy (13.8 %), followed
by Germany (7.8%), Turkey (7.5%), Spain (7.5 %), and then,
as the first non-European country, Japan (6.3 %). By conti-
nent, 71.7 % of abstracts were from Europe, 20.7 % from
Asia, 3.6 % from the Americas, 2.8 % from Africa, and
1.1 % from Australia.
Multidisciplinarity has always been a core value of nuclear
medicine and is reflected by looking at the scientific topics
covered at the meeting. The abstracts were distributed in a
wide range of topics including clinical and basic oncology,
neurosciences, cardiovascular system, radionuclide therapy,
conventional and specialized nuclear medicine, molecular
and multimodality imaging, radiopharmacy and radiochemis-
try, and physics and instrumentation. The numbers of submit-
ted abstracts per category are shown in Fig. 3. Oncological
applications dominate nuclear medicine practice and research.
A great majority of abstracts dealt with oncological science,
led by clinical oncology with 501 abstracts, but also involves
basic oncology (53 abstracts) and radionuclide therapy with
more than 200 abstracts, not to forget that many oncological
topics were covered in other categories such as radiopharmacy
or physics. Other categories were comparably represented
with about 150–190 abstracts in six categories showing the
high research activity in a wide range of topics. Technologists
contributed with their own programme including 137 ab-
stracts. Special tracks stressed the translational aspect from
molecule to man, which was introduced at last year’s meeting
and was well accepted with 264 abstract submissions in this
category. Multidisciplinary aspects of dosimetry and targeted
radionuclide therapy in the DoMoRE track were also of fo-
cused onwith more than 100 abstracts. Most promising for the
future of nuclear medicine was the fact that more than 250
abstracts (15 %) were submitted by young investigators, indi-
cating the interest and activity of young colleagues entering
the field and becoming involved in scientific activities.
All abstracts were rated by expert reviewers and, indepen-
dent of the topic, those with the best individual scores were
considered for the Highlights Lecture. Having the honour and
task to review these abstracts we realized the great potential of
scientists and the great efforts they undertake to bring our
discipline forward. This is really a heroic work, and represen-
tative for all “superhero” scientists we took the task to hunt for
the best science as PETman (Andreas Buck) representing the
clinical science, supported by his friend Robin (Clemens
Decristoforo) looking into basic sciences and highlighting
the translational aspects being representative for this year’s
meeting.
From more than 170 excellent presentations received,
which is highly acknowledged, only 55 were finally selected
and included in the highlights presentation, often being only
examples for a great number of similar and scientifically
equally good submissions related to the limited time available.
So follow PETman and Robin’s hunt for the best science at
EANM’15 meeting in Hamburg.
Oncology: diagnosis
Prostate cancer
Diagnostic imaging in oncology was fueled by a particularly
large number of contributions addressing staging and
restaging of prostate cancer. In a prospective multicenter trial,
Gillenbert and coworkers reported on a series of almost 180
patients undergoing 18F-Choline-PET/CT for detecting bio-
chemical relapse from prostate cancer [1]. This paper nicely
showed the clinical relevance of this established imaging mo-
dality with a significant impact on therapeutic management in
up to 55 % of patients (Fig. 4). However, the positivity rate of
18F-Choline-PET/CTwas as low as 58 %, indicating that this
modality is unable to detect the area of recurrence inmore than
40 %.
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Fig. 1 EANM annual meeting statistics: Submitted, accepted, and
rejected abstracts for the scientific programme in recent years
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This obstacle was specifically addressed by an Italian study
(Morighi et al.) [2]. In a prospective trial comparing 18F-
Fluormethyl-Choline (FMC) and 68Ga-PSMA-PET/CT, sen-
sitivity has doubled using the PSMA-targeted approach as
compared to FMC (Fig. 5). In this series, detection rate of
FMC-PET/CT was as low as 32 and 66 % in the PSMA-
PET/CT group. Two further clinical trials provided evidence
that detection rates of PET imaging in recurrent prostate can-
cer can be further improved using additional targets. Zanoni
et al. from the Bologna group investigated the amino acid
based tracer 18F-FACBC [3]. In a comparative analysis, an
improvement of sensitivity, as well as specificity versus 11C-
choline-PET/CT has been shown. With a sensitivity of 37 %
and a specificity of 67 %, the performance of 18F-FACBC
seems to be in an intermediate position between choline-
based and PSMA-targeted radiopharmaceuticals. An overall
accuracy of 38 %, however, indicates an inferiority of 18F-
FACBC compared to 68Ga-PSMA.
Targeting the bombesin receptor is another approach for
specific imaging of prostate cancer. The concept of using re-
ceptor antagonists has shown success in overcoming limita-
tions, especially in terms of side effects, but also resulting in
improved targeting properties. In a presentation from Bakker
et al. [4], first results in therapy-naïve prostate cancer patients
with [68Ga]Sarabesin 3, a novel GRP receptor antagonist were
reported. In this preliminary study three patients with prostate
carcinoma confined to the prostate were included and imaged
over a period of 3.5 h. No side effects were observed; phar-
macokinetics were favourable with rapid predominant renal
excretion and low background, indicating high metabolic
Fig. 2 EANM’15: Abstracts per
country and continent
Fig. 3 EANM’15: Abstracts per
category
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stability. All patients showed focally increased uptake in the
prostate, which correlated to tumour-GRP expression in auto-
radiography studies after prostatectomy, indicating the suit-
ability of the tracer to image therapy-naïve primary prostate
cancer, confirming the potential of GRP as an alternative to
PSMA-targeting.
Assessing the androgen receptor status is another important
field of PET imaging of prostate cancer, in particular for ther-
apy re sponse eva lua t ion . A nove l PET t race r,
[18F]enzalutamide, was reported by Antunes et al. [5]. Also,
in this case advantages could be expected using an antagonist
to target the androgen receptor. In preclinical studies they
showed that [18F]enzalutamide resulted in higher tumour
uptake, higher tumour/plasma and muscle ratio combined
with a high in vivo stability and lower urinary excretion as
compared to [18F]FDHT, making this compound an interest-
ing and highly promising candidate for translation into human
studies.
Despite the success of [68Ga]HBED-CC-PSMA in the diag-
nosis of prostate cancer, there is still room for further develop-
ment for wider availability of the methodology, enabling in
particular centralized production of PSMA targeting PET li-
gands. In this respect, in this meeting three presentations are
representative for new radiopharmaceutical developments to-
wards PSMA targeting tracers labelled with longer lived radio-
nuclides. Gourni et al. [6] presented a versatile NODAGA-
Fig. 4 Gillenbert et al. [1]
showed in a large prospective
multicenter clinical trial
comprising 177 patients with
biochemical relapse from prostate
cancer that 18F-Choline-PET/CT
has a major impact on the
therapeutic decision making
process in 55 % of patients. An
expert panel rated almost 90 % of
therapeutic changes as adequate.
However, a positivity rate of 58%
indicates that a significant
proportion of patients has
negative imaging results, and thus
do not benefit from PET/CT
imaging
Fig. 5 A variety of scientific presentations have shown superiority of
PSMA-directed radiotracers as compared to choline-based PET tracers.
Morighi et al. [2] have shown that PET sensitivity for detecting the
anatomic site of biochemical relapse has doubled when 68Ga-PSMA is
used as the PET radiotracer. The figure shows focally increased 68Ga-
PSMA uptake in an iliac lymph node metastasis, whereas the
corresponding 18F-Fluoromethylcholine-PET/CT scan showed no
correlate of recurrent prostate cancer
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PSMA conjugate suitable for labelling with 111In for SPECT, as
well as 68Ga and 64Cu for PET imaging. NODAGA-Phe-PheD-
Lys(suberoyl)-Lys-urea-Glu (VG66) showed high affinity and
rapid internalisation on PSMA expressing LNCaP cells, when
radiolabelled with all three radionuclides. Tumour uptake of
68Ga-VG66 (14.5±2.9 % IA/g) in LNCaP xenografts at 1 h
p.i. was comparable to 68Ga-HBED-CC-PSMA (15.8±1.4 %
IA/g) (P=0.67), for 111In-VG66 28.5±2.6 % IA/g were found.
PET-images with 64Cu-VG66 at later time points showed
wash-out from the kidneys, while tumour uptake still remained
high. This holds promise to widen the applicability of the meth-
odology towards SPECTand PETenabling centralized produc-
tion and distribution using 64Cu-labelling.
Two presentations dealt with [18F]-labelled PSMA-li-
gands. Cardinale et al. [7] reported on the radiosynthesis
and preclinical evaluation of radiofluorinated PSMA-ligands
(Fig. 6). They synthesized a series of novel fluorinated
tracers, and optimized biodistribution by introducing a spacer
directing pharmacokinetics towards renal excretion, resulting
in PSMA 1007 with excellent imaging characteristics in
LNCaP tumour bearing mice. Another approach was
attempted by Boschi et al. [8]. They developed an a “one-
pot” method for radiofluorination of the HBED-CC-PSMA
precursor, currently used for 68Ga labelling, using aluminium
[18F]fluoride (AlF), achieving high yields at high specific
activities. In the LNCaP mouse model excellent image con-
trast was achieved.
The coming years will reveal which compound can be suc-
cessfully translated into the clinical setting complementing the
excellent results so far achieved with 68Ga-labelled PSMA
radiopharmaceuticals.
Neuroendocrine cancers
Targeting somatostatin receptor expression for imaging
neuroendocrine tumours represents a mainstay diagnostic
test in daily clinical practice. Skoura and coworkers have
looked at the impact of 68Ga-DOTATATE-PET/CT for
managing patients with neuroendocrine tumours [9]. In a
retrospective cohort comprising 1.258 PET/CT-scans, a
major impact on the therapeutic decision making process
has been described in more than 40 % (515 patients). This
study nicely illustrates the clinical relevance of SSTR-
directed PET imaging in patients with NET and suspicion
on disease recurrence or progression. An interesting study
by Nicolas et al. from the Basel group have presented nov-
el data on radiolabeled somatostatin antagonists for PET
imaging and radionuclide therapy [10]. Initial data from
preclinical models, as well as clinical data indicate that
68Ga-OPS202 provides PET images with high tumour-to-
background ratios and increased tracer retention as com-
pared to 68Ga-DOTATOC, facilitating more sensitive tu-
mour detection (Fig. 7). In addition, dosimetric analyses
in preclinical animal models indicate an improvement of
tumour-to-kidney dose ratio of more than 34 % and signif-
icantly enhance retention in tumour xenotransplants.
Recently, the SSTR-specific theranostic approach has
emerged as a superior imaging and treatment modality for
NET patients. This novel approach using SSTR antago-
nists instead of agonists may further enhance the diagnos-
tic accuracy of SSTR-directed molecular imaging and may
result in improved therapeutic outcomes of patients with
NETs treated with peptide radioreceptor therapy.
Fig. 6 Development of novel
18F-PSMA ligands by Cardinale
et al. [7]. Left: MIPs gained by
PET imaging after injection (2 h
p.i.) of PSMA-tracers shown on
the right side in LNCaP tumour
bearing mice. The arrow indicates
the aim to improve the organ
distribution of PSMA-1003
(upper part of the slide), resulting
in PSMA-1007 (lower part of the
slide). The red oval highlights the
difference in both tracers. The
diagram in the middle shows a
comparison of the organ
distribution of both tracers at 1 h
p.i.
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Intraoperative imaging and navigation
An increasing number of abstracts dealing with sophisticated
imaging modalities for guiding surgical interventions were
recognized during the meeting. Recent evidence that
radioguided surgery can improve success rates, especially re-
garding detection of occult tumour lesions was described by
Pouw et al. from Amsterdam [11]. Using a 3D-freehand
SPECT device, successful detection of occult breast cancer
lesions labelled with 125-Iodine seeds prior to the incision
has been demonstrated. Whereas the vast majority of abstracts
have focussed on lesion localization in breast cancer and mel-
anoma, there were also contributions of radioguided surgery
as integral part of more complex surgical interventions. Of
note, Kleinjahn et al. presented an interesting imaging ap-
proach using a combined radiolabeled and fluorescent probe
for guiding dissection of sentinel lymph nodes in prostate
cancer [12] (Fig. 8).
Other solid neoplasms
A variety of abstracts reported on the diagnostic utility of the
main functional imaging test in oncology, FDG-PET/CT.
Caobelli and coworkers from the Young AIMN Working
Group [13] have nicely shown in a retrospective analysis that
the predictive role of FDG-PET/CT, which was already de-
scribed for the most frequent solid tumours applies also to
patients with ovarian cancer. Whereas an excellent overall
survival has been reported (3-year PFS > 75 %, 4-year
PFS>65 %) in patients with a history of ovarian cancer and
negative PET, a markedly reduced prognosis has been de-
scribed in patients with metastatic disease, as indicated by
FDG-PET/CT (2-year PFS<30 %, 4-year PFS<10 %).
A small but increasing number of abstracts provided further
evidence on the clinical utility of fully integrated PET/MRI
systems. Marner and coworkers have presented initial data
from an ongoing prospective clinical trial in children with
malignant brain tumours [14]. PET/MRI seems to be especial-
ly relevant in children to reduce the overall radiation burden
caused by medical imaging. In a sub-cohort comprising 31
patients with newly diagnosed brain tumours, PET/MRI had
a major impact on the therapeutic management in two patients
and a minor impact in 15 patients, respectively.
Investigations on novel targets for oncological diagnosis
are essential to advance further nuclear medicine’s role in
oncology, and several presentations tackled this, but only
one could be highlighted as a representative example. Luo
et al. [15] used a recombinant human hepatocyte growth factor
(rh-HGF) radiolabelled with 64Cu to target c-Met, the receptor
for HGF. They conjugated NOTA for radiolabelling and could
show retained binding to c-Met in a set of in vitro experiments.
PET imaging in tumour bearing mice revealed specific and
prominent uptake of 64Cu-NOTA-rh-HGF in c-Met positive
U87MG tumours (6.7±1.8 %ID/g and significantly lower up-
take in c-Met negative MDA-MB-231 tumours (1.8
± 0.6 %ID/g). This excellent and specific c-Met targeting
makes this a promising compound for assessing c-Met expres-
sion, which can be extremely useful for monitoring of re-
sponses to c-Met-targeted therapies, but can also provide a
basis for targeted radionuclide therapy, which was a major
outstanding scientific topic at this meeting.
In summary, significant improvements of molecular imag-
ing for managing patients with prostate cancer and neuroen-
docrine tumours were shown. PSMA-PET/CT appears to be a
new gold standard for staging and restaging of prostate cancer.
Novel tumour specific compounds may be used for target
Fig. 7 Use of somatostatin
receptor antagonists instead of
agonists results in an
improvement of tumour-to-
background ratio in
neuroendocrine tumours. Nicolas
and coworkers presented novel
data on the utility of the SSTR
antagonist 68Ga-OPS202 which
showed an improvement in
sensitivity (right) as compared to
the standard imaging approach
using radiolabelled SSTR
agonists (68Ga-DOTATOC, left)
[10]. Ultimately, in a theranostic
setting, SSTR antagonsits may
also improve therapeutic outcome
after peptide radioreceptor
therapy (PRRT)
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identification and understanding the heterogeneity of solid
cancers. In addition, nuclear imaging techniques appear to
enter the operating room soon.
Oncology: therapy
Preclinical highlights
A large number of preclinical presentations included work on
new targets, radiopharmaceutical tools to improve targeting
efficiency, new radionuclides including alpha emitters, but
also investigations into mechanisms of targeting and efficacy
of radionuclide therapy approaches, three examples are repre-
sentative for the high research activity in this field.
This year’s Marie Curie award paper from Honarvar et al.
[16] dealt with the affibody molecule-based PNA-mediated
pre-targeting (Fig. 9). Radiolabelled affibodies have shown
great promise to serve as a platform for antigen targeting:
however, they have high kidney uptake and retention, limiting
their potential for radionuclide therapy. Honarvar et al. used
in vivo hybridisation based on peptide nucleic acids (PNA)-
mediated pretargeting to modify and thereby improve phar-
macokinetics. Preinjection of PNA conjugated anti-HER2
affibody followed by 111In-labelled complementary DOTA-
PNA resulted in higher and highly specific tumour uptake,
combined with dramatically reduced kidney retention in a
mouse tumour model, as compared to the 111In-labelled
affibody itself. This novel pretargeting approach enables spe-
cific delivery of radionuclides to tumours providing improved
radiometal concentration in tumours and reducing non-target
accumulation applicable to affibodies, but with the potential to
be more widely applied for targeting vectors for therapeutic
applications.
Pouget et al. [17] investigated the relative contribution of
direct and indirect (bystander) effects in the therapeutic effi-
cacy of alpha emitting 212Pb-labeled mAbs in small volume
peritoneal carcinomatosis model. In a complex series of
in vivo and in vitro experiments comparing anti-CEA and anti
Her2 MAbs they showed that despite the strong direct effects
of 212Pb-labeled mAbs in killing tumour cells, there is a strong
contribution of the bystander effects resulting in good thera-
peutic results even when mAbs show a high heterogenous
tumour distribution. More studies like these are warranted to
increase our understanding in therapeutic efficacy of specifi-
cally targeted radiopharmaceuticals for therapy to optimize
the tracer design, select the most effective and safe radionu-
clides and direct the timing and activity of administration.
The optimal selection of targets for radionuclide therapy
approaches also is dependent on tumour grade and type.
Dalm et al. [18] investigated the clinical relevance of targeting
SSTR2, GRPR, and CXCR4 with radioligands for imaging
and therapy in breast cancer samples. They established a cor-
relation of mRNA levels (PCR) and receptor expression of
Fig. 8 KleinJahn and coworkers [12] reported on an innovative approach
for intraoperative imaging of sentinel lymph nodes (SLN) in patients with
prostate cancer. They have shown the feasibility of SLN dissection using
multimodal imaging. 1A, 3D volume rendering showing the SNs; 1B,
fused SPECT/CT with SN; 1C, da Vinci Si robot with integrated
fluorescence laparoscope; 2A, White light image illustrating the area
harbouring the SN; 2B, fluorescence guidance clearly shows the
contours of the SN; 3A, distribution of the sentinel nodes inside the
ePLND area; 3B, distribution of the SN outside the ePLND area. In
green the in vivo fluorescent SN and yellow the SN that were only
radioactive in vivo
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SSTR2 and GRPR (autoradiography) and subsequently inves-
tigated mRNA levels of SSTR2, GRPR, and CXCR4 in 915
clinical breast cancer samples, which they associated with
known clinicopathological factors and prognosis. They found
a positive correlation between high GRPR/SSTR mRNA
levels and estrogen and progesteron receptor positive tumours
indicating that GRPR and SSTR2 mediated imaging and ther-
apy can be especially beneficial for this patient group, whereas
high CXCR4mRNA levels were correlated with receptor neg-
ative tumour indicating that triple negative breast cancers, for
which effective therapy options are scarce, are an interesting
subtype for application of CXCR4 radiotracers. In 1st line
tamoxifen treatment a significant correlation between high
GRPR mRNA levels and prolonged PFS after start of 1st line
Tamoxifen treatment was established, indicating that GRPR
expression has predictive value for the efficacy of tamoxifen
therapy. This is an excellent example of a study that improves
our understanding on how especially novel targeted radionu-
clide therapy approaches can be optimally translated into the
clinical setting.
Prostate cancer
Striking results have been presented by Kratochwil and co-
workers from the University of Heidelberg demonstrating
antitumour activity of 177Lu-PSMA617 in metastatic
hormone-refractory prostate cancer [19]. A total of 30 patients
have undergone three treatment cycles in intervals of 2 months
each (Fig. 10). In this heavily pretreated patient cohort, a
significant drop of PSA values were reported after a single
treatment cycle in 70 % of patients. After a third treatment
cycle, reduction in PSA levels was >50 % in more than
70 % of patients, indicating highly effective tumour cell kill.
Hence, PSMA directed radionuclide therapy represents a nov-
el treatment strategy especially for patients with heavily
pretreated metastatic disease.
Kulkarni and coworkers from the Bad Berka group have
shown similar results in a related set of patients with recurrent
prostate cancer [20]. After two courses of PSMA-directed
treatment, a significant drop of PSA-values>58 % has been
demonstrated. These excellent and promising results for pa-
tients with advanced metastatic disease were complemented
by theoretical considerations on further optimizing peptide
radioreceptor therapy in prostate cancer. As an example,
Kletting and coworkers [21] developed a physiologically
based pharmacokinetic (PBPK) model on the most suitable
ratio of radioactivity and the amount of peptide used for
radiolabeling. They calculated a more rapid saturation of
non-target organs (i.e., kidney, salivary glands) than in tu-
mours, which can be the basis of further optimizing targeted
tumour therapy with PSMA-ligands.
Other solid tumours
Specific melanoma cell targeting using the benzamide deriv-
ative 131I-BA100 was shown by Spohn and coworkers [22]. In
a preliminary study comprising 10 patients with metastatic
melanoma, this novel therapeutic approach was applied on a
Fig. 9 Depiction of the presentation of Honarvar [16]. The imaging has
been done from SKOV-3 xenograft bearing mice using clinical gamma
camera. All animals were injected with 650 kBq of a radiolabeled
compound 1 h before the image acquisition. A single image of all
animals was simultaneously acquired. Left mouse: animals were pre-
injected with 100 μg ZHER2:342-SR-HP1 4 h prior to injection of
1 μg 111In-HP2. Middle mouse: 111In-HP2 was injected with 111In-HP2
without pre-injection of ZHER2:342-SR-HP1. Right mouse: animals
were injected with 2 μg 111In-DOTA-ZHER2:K58 (650 kBq)
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compassionate use base. The study shows significant
antitumour activity at least in a fraction of patients, supporting
this interesting approach for radionuclide-based therapies in
melanoma.
Selective internal radiotherapy is currently used for non-
resectable primary liver tumours and liver dominant metasta-
tic disease from solid tumours [23]. Prince and coworkers
showed a new 166Ho-microsphere based embolization proce-
dure, resulting in a significant delay of tumour progression in
almost 60 % of patients. If this holmium based approach im-
proves the therapeutic success already demonstrated for 90Y-
labelled microspheres remains to be determined.
Novel targeted therapeutic approaches have been presented
also for malignant brain tumours (Królicki et al.) using 213B-
labeled DOTA-substance P [24]. The authors demonstrated
that this approach is safe and well tolerated, resulting in PFS
of 3.7 months. Targeting metastatic renal cell cancer using the
carbonic anhydrase nine specific antibody 177Lu-
gerentuximab was shown by Muselaers et al. from
Nijmwegen [25]. Apart from transient myelotoxicity, the ther-
apy was well tolerated and resulted in disease stabilization in
64 % of patients with progressive disease.
Whereas specific tumour targeting, safety, and tolerability
has been shown in a number of novel targeted nuclear therapy
techniques, overall outcome regarding disease stabilization
and survival has to be assessed in prospective clinical trials
for these compounds. First results from such a prospective
trial were reported by Pryma et al. [26] from the United
States. A phase II study evaluating Ultratrace® (iobenguane)
for treatment of metastatic paraganglioma or pheochromocy-
toma showed its safety and tolerability. Moreover, the impor-
tance of patient-specific treatment planning by dosimetry was
highlighted. Several papers have indicated that radionuclide
based treatment in combination with other tumour directed
therapies may improve the overall outcome. In an interesting
study presented by Boni and coworkers, 131I-MIBGwas com-
bined with chemotherapy for treatment of high-risk neuroblas-
toma [27]. Whereas only preliminary data were shown, this
approach seems suitable to enhance further success rates of
radionuclide based treatments.
Hematological neoplasms
Some striking data were reported by Herrmann and coworkers
[28]. The chemokine receptor-4 (CXCR4) emerges as a novel
target for imaging and treatment, particularly of hematological
neoplasms. In a preliminary study comprising patients with
multiple myeloma, highly effective antitumour activity was
demonstrated using 177Lu- or 90Y-labelled CXCR4-specific
ligands (Pentixather®), eradicating not only bone marrow re-
lated myeloma lesions, but also soft tissue and other
extraosseous lesions (Fig. 11). Currently, this approach has
been reported to be used also for treatment of other,
CXCR4-positive solid tumours.
Whereas radioimmunotherapy targeting the CD20-antigen
has been available for more than 13 years, a novel target has
been used by Dahle et al. [29]. In a preclinical animal model,
excellent tumour retention in lymphoma xenotransplants was
demonstrated with advantages of chimeric vs. murine versions
of the HH1 antibody targeting the CD37 antigen. In a related
presentation by Stokke and coworkers [30], a phase1 clinical
data using 177Lu-DOTA-antiCD37 (Betalutin®) indicated sig-
nificant antitumour activity. This approach may widen the
therapeutic spectrum especially in patients with CD20-
refractory lymphoma.
In summary, novel theranostic concepts addressing also
highly frequent tumour entities including prostate cancer, mel-
anoma, and lymphoma were presented. Obviously, due to
Fig. 10 Striking therapeutic
activity of 177Lu-PSMA617 has
been presented byKratochwil and
co-workers from the University of
Heidelberg [19]. (a) indicates
multifocal metastatic disease to
the bone at 68Ga-PSMA-PET/CT
of a patient with progressive
prostate cancer. After three cycles
of treatment (b), PSMA-positive
lesions completely resolved (c)
and PSA-values decreased from
an initial value of 387 ng/mL to
1.08 ng/mL
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effective tumour cell kill and only mild to moderate side ef-
fects, an increasing role of targeted radionuclide therapies can
be envisioned. Furthermore, already established radionuclide-
based therapies may be further improved by using novel com-
pounds such as SSTR-directed antagonists, further enhancing
sensitivity of PET imaging and enhancing antitumour activity
by increasing the delivered dose to the tumour.
Neuroscience
Accessibility to new PET tracers especially in neurosciences
depends on developments in radiochemistry. Among several
submissions two presentations should be highlighted. Taddei
et al. [31] presented a novel, quick, and reliable method to
convert [11C]CO2 to [
11C]CO, mediated by a [11C]silane de-
rivative generated in situ and triggered by an activator. Using
readily available labware, an automated system was devel-
oped giving simplified access that could lead to increased
availability of [11C]CO chemistry to the PET community.
Related to F-18, Zischler et al. [32] reported on the efficient
product ion of PET tracers via copper-media ted
radiofluorination under so called minimalist conditions.
Us ing coppe r med i a t ed a roma t i c nuc l eoph i l i c
radiofluorination of (mesityl)(aryl)iodonium salt precursors
[18F]fluorodopamine, [18F]4-fluorophenylalanine and [18F]-
DAA1106, a promising tracer for visualization of neuroin-
flammation, were prepared in 46–66 % radiochemical yields.
Specific activities of >60 GBq/μmol were achieved. This
radiofluorination method that combines the advantages of
“minimalist” approach to radiolabelling with the exceptional
capabilities of copper mediated aromatic nucleophilic
radiofluorination, opens newways for the efficient preparation
of a number of interesting radiopharmaceuticals especially for
neurolological applications.
Additionally, this meeting was characterized by a number
of submissions on the development of improved ligands and
preclinical characterisation of developed ligands in novel pre-
clinical models for various highly interesting targets in neu-
rology and psychiatry. Rami-Mark et al. [33] presented the
preclinical evaluation of a new 11C-tracer for the norepineph-
rine transporter (NET), [11C]Me@HAPTHI. This tracer
showed an excellent affinity (KD=0.21±0.07nM) and selec-
tivity (DAT/NET>1940; SERT/NET=9700) for the NETand
high metabolic stability. In autoradiographic experiments on
human brain tissue, highest uptake was observed in NET-rich
regions and a concentration dependent binding displacement
observed. This promising compound awaits further in vivo
evaluation for translation into the clinic.
Gargiulo et al. [34] used [18F]DPA-714 to image
translocator protein-expression (TSPO, a marker for neuroin-
flammation), in a mouse model of amyotrophic lateral sclerosis
(ALS) via μPET/CT. In the SOD1G93A symptomatic mice,
the region/frontal cortex ratio was significantly increased
(p=0.012) in the brainstem (2.340±0.784) as compared to
non-carriers wild type mice (1.576±0.287). These preliminary
results suggest that increased [18F]DPA-714 uptake can be
measured with high resolution PET/CT in a mouse model of
ALS in the brainstem, a region known to be the site of degen-
eration and increased microglial activation. Correlating with
positive immunostaining of TSPO in the brain stem suggests
that increased microglial activation might be the cellular coun-
terpart of in vivo increased [18F]DPA-714 uptake and provides
a basis for ALS imaging by means of PET.
Another TSPO targeting ligand ([11C]PBR28) was used by
Toth et al. [35] for longitudinal imaging of acute neuroinflam-
mation in a rat ischemic stroke model by micro-PET. They
monitored the inflammatory response after transient cerebral
ischemia in rats, using a recently developed rat stroke model
with isolated focal cortical infarcts. [11C]PBR28 showed high
uptake in the infarct region from day 4 with gradual decrease
Fig. 11 Impressive therapeutic
activity of 177Lu-CXCR4
(Pentixather®) presented by
Herrmann et al. [28]. On the left
hand side, partial response of a
patient with multiple myeloma
lesions in the bone can be seen at
FDG-PET/CT 14 days after
therapy. The images on the right
show almost complete remission
14d after CXCR4-directed
therapy
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at later time points. The longitudinal follow-up of inflamma-
tory response with the TSPO radioligand [11C]PBR28 showed
significantly up-regulated TSPO binding in the infarct region
from day 4, with both %SUV and binding potential opening
new possibilities for studies on neuroinflammation in ische-
mic stroke.
[18F]-THK-5117 is a promising PET tracer for imaging
abnormal accumulation of tau aggregates in brain as one of
the hallmarks of Alzheimer’s disease. Brendel et al. [36] eval-
uated the radioligand [18F]-THK-5117 in different mouse
models (P301S1, biGT2, Tau223) of tau pathology using
μPET in combination with autoradiography and histopathol-
ogy. They showed that Tau imaging in mice is feasible and
correlates with ex vivo findings. The Tau 22 model was best
suited to image pathology-related effects. This in vivo assess-
ment of the given inter-animal heterogeneity can, therefore,
potentially improve subsequent treatment studies in the future.
The in vivo evaluation of a novel ligand ([11C]preladenant)
for the adenosine A2A receptor, a therapeutic target in several
neurologic and psychiatric disorders, was presented by Zhou
et al. [37]. They imaged [11C]preladenant in conscious mon-
keys; caffeine pretreatment reduced the tracer uptake in stria-
tum in a dose-dependent manner. Kinetic modelling allowed
to estimate binding potential in striatum and to quantify
A2AR density (Fig. 12). [11C]Preladenant PET was suitable
to noninvasively quantify A2ARs in monkey brain and holds
great potential to translate this into the clinical setting.
Numerous excellent papers were also found in the human
application in neurosciences. Gejl et al. [38] presented results
from a randomized, placebo-controlled, double-blinded clini-
cal trial investigating the effect of the GLP-1 analogue
liraglutide on the decline of brain glucose metabolism in
Alzheimer’s disease. In this PET study they compared the
results of 11C-PIB (as marker for amyloid plaque) and FDG
(as a surrogate marker of synaptic dysfunction and neuronal
activity) imaging in a group treated with liraglutide (n=18) or
with placebo (n=20) in a 26-week interval. In both groups,
amyloid plaque deposition significantly increased, but no dif-
ference between the groups was found. Cerebral metabolic
rate of glucose (CMRglc) measured by FDG-PET, however,
declined significantly in the placebo group, whereas
liraglutide medication resulted in a numerical, albeit insignif-
icant, increase of CMRglc after the 6 months of treatment
(Fig. 13). Liraglutide treatment, therefore, prevented the de-
cline of CMRglc seen in untreated Alzheimer’s patients where
it signifies cognitive impairment, synaptic dysfunction, and
disease evolution.
New PET tracers PET could play an increasing role also in
Parkinson’s disease, allowing in particular improved means of
quantification. Sonni et al. [39] reported on the applicability of
a simplified quantification of the dopamine transporter using
the novel dopamine transporter ligand [18F]FE-PE2I. In 10 PD
patients and 10 control subjects they identified the optimal
acquisition time window between 16.5 and 42 min to the
Fig. 12 In vivo evaluation of [11C]preladenant for imaging of adenosine
A2A receptors in the conscious monkey [37]. The tracer kinetics in the
monkey brain is well described with the 2-tissue compartment model and
Logan graphic analysis with metabolite corrected plasma input function.
Figure 1a shows the good correlation in distribution volume between 2-
tissue compartment model and Logan plot. Binding potential was
estimated with multilinear reference tissue model. The value was in
agreement with binding potential calculated from distribution volume
ratio (DVR)-1, as is shown in Fig. 1b. Caffeine pretreatment reduced
the tracer uptake in striatum in a dose-dependent manner (Fig. 2).
Figure 2b shows that the standardized uptake values in striatum
(putamen and caudate) correspond to baseline (open circle), and 2.5
(triangle), 5 (cross), 10 (closed circle) mg/kg caffeine pretreatment
(A2AR occupancy 52, 63, and 81 % for 2.5, 5, and 10 mg/kg caffeine,
respectively)
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determine specific binding ratio (SBR) that is in closest agree-
ment with the binding potential. Despite an underestimation of
BPND, and possibly decreased sensitivity to detect
nigrostriatal deficit, the SBR can be viewed as a valid quanti-
fication method for DAT using [18F]FE-PE2I for diagnostic
purposes, since it provides similar differentiation as BPND
between normal and Parkinson’s patients, thereby allowing
translation of quantitative PET dopamine transporter imaging
into a routine clinical setting.
The clinical impact of amyloid PET imaging has been a
matter of debate over the last years. In a highly interesting
clinical study Pontecorvo et al. [40] investigated the impact
of florbetapir (18F) PET amyloid imaging on patient manage-
ment and outcome. This randomized, controlled, multicenter,
international trial included 618 patients with MCI or demen-
tia, where AD was considered a possible cause (<85 % cer-
tain). Patients underwent a florbetapir PETscan and were then
randomized to either immediate (n=308) or delayed (1 year,
n=310) feedback regarding amyloid status (positive: Aβ+,
negative: Aβ-). After 1 year, treatment was changed in
32.3 % in the group with immediate feedback, whereas only
in 8.2 % in the delayed feedback group. Ach-inhibitor medi-
cation was 74 % (Aβ+) vs. 23 % (Aβ-) in the immediate as
compared to 56 % (Aβ+) vs. 41 % (Aβ-) in the delayed
feedback group. This is the first large multicenter randomized
controlled study of the clinical impact of amyloid PET and
may help guide and strengthen the use of amyloid PET
imaging.
Overall, this meeting confirmed the high translational po-
tential of nuclear medicine in neurosciences. Novel tools in
radiochemistry provide the basis for better accessibility of
radiotracers, characterisation in novel disease models open
new opportunities in preclinical research, also strengthened
by improved tracers for known targets. A number of targets
of high interest in neurology and psychiatry are now accessi-
ble for PET imaging including A2A, TSPO, NMDA, and
many more giving great new opportunities for clinical appli-
cation and research on nuclear medicine and particular PET in
neurosciences.
Cardiovascular
In the cardiovascular tract, a significant fraction of
submitted abstracts focused on further improvement
of myocardial perfusion imaging. An interesting con-
tribution by Caobelli and coworkers [41] has demon-
strated significant reduction of the scan duration using
IQ-SPECT. Myocardial perfusion imaging was per-
formed using reduced acquisition time of just one
eighth or one quarter of the standard scanning time
(Fig. 14). The authors adequately showed that image
Fig. 13 In AD patients,
liraglutide treatment prevented
the decline of CMRglc seen in
placebo-treated patients where it
is considered to signify cognitive
impairment, synaptic
dysfunction, and disease
progression [38]
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quality was somewhat reduced, but did not affect di-
agnostic accuracy.
Despite savings in acquisition time, reduction of radiation
burden and enhanced motion correction were also major is-
sues, which have been addressed by several contributions. In a
relevant study presented by Liu and coworkers from Sydney,
submillisievert stress perfusion imaging was evaluated [42].
Using a novel cadmium zinc telluride SPECT camera in com-
bination with a CT device (CZT SPECT/CT) and reduced
activity of only 100 MBq, a superior image quality was
achieved. Data derived from the calcium scoring CT were
used for correction of attenuation artefacts.
Motion correction using a similar device was presented by
Redgate and coworkers [43]. Adequate motion correction
could be performed by summing reconstructed 33 images.
They showed that this is technically feasible and accurate,
improving outcome of cardiac studies.
An interesting study was provided by Rijnierse et al. from
Amsterdam [44]. Using multimodal imaging techniques, the
role of myocardial perfusion imaging, detection of sympathet-
ic denervation and scar size were used to assess their predic-
tive role on detecting inducible ventricular arrhythmia in pa-
tients with ischemic cardiomyopathy. [15O]H2O-PET for
myocardial perfusion imaging and [11C]HED-PET for inner-
vation imaging has been performed. Of interest, impaired hy-
peremic perfusion of the left myocardium was the only inde-
pendent predictive parameter of ventricular arrhythmia. Scar
size, sympathetic denervation, and an obvious innervation-
perfusion mismatch were of less significance. Another rele-
vant study related to coronary artery disease was presented in
the technology track. Kan and coworkers assessed the fre-
quency of side branch occlusion after stenting of the ramus
descendens anterior (RDA) [45]. Using [13N]NH3-PET for
myocardial perfusion scanning, they showed that side branch
occlusion occurred in a relevant proportion of the total patient
cohort (38 %). However, defects were usually small and di-
minished completely at rest perfusion scanning. Knowledge
of side branch occlusion in a relevant fraction of patients un-
dergoing RDA stenting is relevant for interpreting myocardial
perfusion scans in daily clinical practice.
Despite coronary artery disease, other cardiac illnesses
have been in the focus of a variety of contributions. In a pre-
liminary study, Sgart and coworkers have shown that FDG-
PET/CT in combination with cardiac MRI could be used not
only to identify cardiac involvement of sarcoidosis, but also to
monitor response to treatment [46]. Dellavedova and co-
workers from Milan have shown that the uptake of FDG in
the vessel wall of patients with large vessel vasculitis can be
used as a prognostic marker, identifying patients with a more
complicated course of the disease or disease progression [47].
This information could be used by clinicians to further guide
therapeutic interventions.
Imaging of vulnerable plaque represents a so far unmet
clinical need. The CXCR4-directed PET probe 68Ga-
Pentixafor® developed by H.J. Wester at TUMunich has been
assessed in a rabbit model of arteriosclerosis by Hyafil and
coworkers [48]. The authors have shown specific retention of
the radiotracer in experimental arteriosclerotic plaques of the
carotid artery. CXCR4-specific retention was proven also by
an adequate control (non-inflamed vessel wall) and correlation
Fig. 14 Caobelli and coworkers
[41] assessed the feasibility of
reducing scanning time for
myocardial perfusion scanning by
one quarter and one eighth using
the IQ SPECT system. They have
shown somewhat reduced image
quality (left images, upper and
lower panel) at 6 s/view as
compared to 12 s/view acquisition
time (right images, upper and
lower panel), whereas summed
scores were equivalent using both
acquisition protocols
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to corresponding immunohistochemical sections stained for
CXCR4-expression (Fig. 15).
In summary, a variety of presentations focused on further
optimization of cardiac imaging by reducing the radiation ex-
posure to the patient, reducing scanning time and further op-
timizing motion correction. Of interest, several contributions
addressed molecular imaging of inflammation in the cardio-
vascular system. Specifically, large vessel vasculitis and car-
diac sarcoidosis were major diseases of interest which were
addressed also by novel radiopharmaceuticals targeting che-
mokine receptor expression.
Conventional nuclear medicine: miscellaneous
Besides the major topics oncology, cardiology, and neurosci-
ences, also almost 200 abstracts accounted for topics outside
this mainstream and covered a great variety of diseases. An
example of research on a novel thyroid targeting agent was
presented by Galli et al. [49], who reported on further im-
provements towards radiolabelled TSH analogues. They com-
pared two new 99mTc-labelled superagonist rhTSH analogues
for imaging poorly differentiated thyroid cancers. 99mTc-
TR1402 proved superiority over 99mTc-TR1401 and 99mTc-
thyrogen with high affinity to the receptor, a high focal uptake
in mice bearing TSHR-cells and excellent imaging properties
in dogs with spontaneous intra-glandular papillary thyroid
cancer, in which TSHR expression was confirmed by immu-
nohistochemistry, opening new perspectives for pre-surgical
TSHR-based staging of thyroid cancer, for diagnosis of
radioiodine negative cancer remnants, local relapse, and/or
distant metastases.
An excellent clinical study using 99mTc-CXCL8 SPECT to
image disease activity in inflammatory bowel disease was
reported by Aarntzen et al. [50]. In a total of 30 patients (17
Crohn’s disease, 14 ulcerative colitis) uptake of 99mTc-
CXCL8 in intestinal lesions was significantly increased dur-
ing exacerbations, as compared to scans performed during
follow-up. They demonstrated that 99mTc-CXCL8 SPECT
has an excellent diagnostic accuracy on a per-segment analy-
sis, as compared to endoscopy and is a non-invasive whole
body alternative for endoscopy to monitor disease activity in
inflammatory bowel disease (Fig. 16).
Also, well-established radiopharmaceuticals and nuclear
medicine imaging techniques still have a strong clinical utility,
as shown in a number studies presented at the meeting.
Medaer et al. [51] looked at the impact of colonic transit scin-
tigraphy on clinical decision making in severely constipated
children. Ten patients with chronic treatment-resistant func-
tional constipation received an 111In-DTPA colonic transit
scintigraphy. The results of the scintigraphy lead to a change
in management in 9/10 patients and had therapeutic
Fig. 15 Hyafil et al. [48] presented innovative work using the novel
chemokine receptor 4-specific radiotracer Pentixafor® for imaging
vulnerable plaques. In a canine model of vascular inflammation,
CXCR4-specific retention of the radiotracer was shown in
atheroscleoritic plaques, whereas no tracer uptake was detected in the
normal vessel wall. Upper left: intense uptake of pentixafor in the right
atherosclerotic carotid artery (PET-MRI). Biodistribution studies
confirmed specific binding of pentixafor in atherosclerotic plaques,
which was inhibited by blocking after co-injection of a CXCR4
inhibitor (lower left panel). Higher pentixafor uptake (red color) was
detected in atherosclerotic plaques as compared to control arteries
(upper right panel). Intense expression of CXCR4 in atherosclerotic
plaques (brown staining) was identified in carotid plaques bi immuno-
histology in the rabbit model (lower right panel)
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consequences 7/10 patients. This preliminary study demon-
strates the added value of colonic transit scintigraphy, an old
technique, in the investigation of functional constipation in
children and the high impact on clinical decision making.
Physics and instrumentation
Last, but certainly not least also physics and instrumentation
contributed significantly to the scientific excellence of this
meeting. A number of great innovations were reported regard-
ing to new instruments opening many opportunities both for
clinical and preclinical imaging.
Beekman et al. [52] developed a new full-ring stationary
clinical SPECT system, G-SPECT-I, based on a stationary ring
consisting of nine large field-of-view cameras with
595×472 mmNaI crystals, a 3D stage that allows optimal sam-
pling during scanning, and an interchangeable nonagon-shaped
collimator containing 54 pinhole apertures and with a bore di-
ameter of 398 mm that makes the system suitable for brain,
extremity, or pediatric imaging (Fig. 17). Using resolution phan-
toms, a comparison was made with dual head SPECTwith low
energy high resolution collimators and 3DOSEM. Smallest rods
resolved with G-SPECT-I where 2.5 mm as compared to 7 mm
with a conventional dual head SPECT. Peak sensitivity of G-
SPECT-I was 630 cps/MBq compared to 182 cps/MBq for dual
Fig. 16 99m Tc-CXCL8 in inflammatory bowel disease [50]. Left: a
patient with ulcerative colitis in an exacerbation phase of the disease,
showing severe disease activity involving all segments of the colon,
from ascending colon (but not terminal ileum), transverse colon through
the sigmoid. Right: a per-segment analysis of the grading according to the
99m Tc-CXCL8 SPECT, measured as compared to bone marrow, which
has a stable level of 99m Tc-CXCL8 uptake during both exacerbations and
quiet phases of disease, and according to the pathologist. In grey scale, the
number of evaluated segments are shown. At both ends of the spectrum,
no disease activity or severe, the correlation was excellent, no false
negatives, a few false positives mainly located in the ascending colon
Fig. 17 Properties of a novel
SPECT system (G-SPECT) [52].
Left top: Comparison of phantom
imaged on a conventional double
head camera as compared to G-
SPECT: equal acquisition time
and dose shows superb resolution
for G-SPECT. Right top:
Hoffman brain phantom shows
uptake in small structures.
Bottom: A clock was put in the
scanner with 0.1 MBq 99m Tc on
the second hand. This shows that
a tremendous speed can be obtain
with G-SPECT, opening up new
possibilities for fast dynamic
studies
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head; dynamic imaging with time frames of <10 s was possible
for focused scans. This excellent spatial and time resolution
combined with a high sensitivity potentially opens new oppor-
tunities for SPECT imaging.
Several papers reported on new technical developments for
preclinical imaging, reducing size, or improving resolution or
sensitivity. Segbers et al. [53] showed first images with the
Mediso nanoScan preclinical SPECT/MR system. High reso-
lution SPECT imaging (<0.9 mm using a multi-pinhole
SPECT subsystem with four rotating 9.5 mm NaI detectors)
and accurate quantification of tumour uptake within 11 % was
possible providing fused MRI images (using a 1 Tesla mag-
net) with clear anatomical details in normal animals and tu-
mour xenotransplant models.
Also, new clinical applications can be expected in the fu-
ture based on new imaging technologies. The general idea and
the functionality behind a so-called Real-time Handheld
Emission Spot Allocator (rthESA) for Simultaneous Fusion
of Nuclear Imaging with Ultrasound was presented by
Kühnel et al. [54]. The rthESA prototype to allocate a radio-
active spot source is based on electronic collimation, capable
of assessing the distance of the source from the detector,
avoiding the need for classic reconstruction thereby allowing
real-time imaging. This was physically combined with an ul-
trasound probe and both devices depict the same plane in an
imaging model. Such an imaging modality would open new
ways for imaging in a variety of clinical challenges.
Also in image reconstruction a number of new approaches
were reported. Engberg et al. [55] used voxel-wise analysis for
multiparametric characterization of early tumour response by
PET/MR in patients with lung cancer. Eight patients with his-
tologically or cytologically confirmed lung cancer underwent
simultaneous FDG-PET/MRI (Siemens mMR) prior and
different days after the first or second cycle of chemo-
therapy. Multiparametric imaging with simultaneous
FDG-PET and DW-MRI in lung cancer patients allowed
identification of a responding pattern by voxel-wise GMM
analysis already 24 h after chemotherapy, potentially enabling
a rapid shift to a more efficient therapy in nonresponding
patients.
Eberlein et al. [56] analysed DNA double strand break
biomarkers γ-H2AX and 53BP1 in lymphocytes of 16 pa-
tients during their first peptide receptor radionuclide therapy
and 20 patients during radioiodine therapy of differentiated
thyroid cancer. The number of radiation induced foci (RIF)
as a function of time was characterized by a linear dose-
dependent increase and a multi-exponential decay function
characterizing different rates of DNA repair. If the absorbed
dose to the blood exceeded 20 mGy in the first hour, on-set of
a fast repair component (only observed in DTC patients)
resulting in a bi-exponential repair function was observed;
otherwise a mono-exponential function better described the
repair of the double strand breaks. This study revealed a
threshold dose of 20 mGy within the first hour for the induc-
tion of a fast repair component after in vivo double strand
break induction.
Finally, a study is highlighted dealing with radiation dose
during routine clinical imaging. Johnsen et al. [57] studied the
cumulative radiation dose received by diagnostic imaging in 20
children and young adults diagnosed with primarily operable
Ewing Sarcoma diagnosed in Norway in the period 2005 to
2012, without metastases or residual disease in a follow up
period of 1 year after diagnosis. The estimated mean cumula-
tive radiation dose of patients received during the first year after
diagnosis was 39 (6–86) mSv, the contribution from nuclear
medicine imaging was 22 mSv. PET/CT imaging contributed
to only 15 % of the total radiation dose the study revealed a
wide range of diagnostic imaging modalities and examination
performed on this patient group. This is an excellent example of
studies required to prove the suitability and rationale of all new
innovations we foresee with nuclear medicine techniques in the
years to come to use them in the best way for our patients.
Conclusion
The 2015 annual congress of the European Association of
Nuclear Medicine is an excellent example for the increasing
number of functional and molecular imaging techniques be-
coming available in recent years. In addition, the clinical rel-
evance of nuclear medicine is fueled by a number of targeted,
radionuclide based treatment approaches. Effectiveness re-
garding diagnostic accuracy as well as therapeutic activity
has been shown for many clinical scenarios. Further evidence
of the clinical utility has been provided by joint forces of basic
scientists including physicists, chemists, biologists, pharma-
cists, engineers, as well as technicians and medical doctors.
Bringing all these specialties together and addressing a
plethora of yet unmet clinical needs is a heroic work and many
“superhero scientists” have been identified at the 2015 EANM
meeting contributing to various research activities.
Collaborations with superheroes also of other medical disci-
plines, including—among others—oncologists, cardiologists,
neurologists, radiation oncologists, and surgeons, will pave
the way for the widespread acceptance of these novel imaging
techniques and treatments, becoming a future standard for
imaging and therapy of our patients.
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